NZ585298A - Carboxamide, sulfonamide and amine compounds for metabolic disorders - Google Patents
Carboxamide, sulfonamide and amine compounds for metabolic disordersInfo
- Publication number
- NZ585298A NZ585298A NZ585298A NZ58529808A NZ585298A NZ 585298 A NZ585298 A NZ 585298A NZ 585298 A NZ585298 A NZ 585298A NZ 58529808 A NZ58529808 A NZ 58529808A NZ 585298 A NZ585298 A NZ 585298A
- Authority
- NZ
- New Zealand
- Prior art keywords
- piperidin
- carboxamide
- sulfonamide
- metabolic disorders
- yloxy
- Prior art date
Links
- 150000003857 carboxamides Chemical class 0.000 title abstract 2
- 208000030159 metabolic disease Diseases 0.000 title abstract 2
- -1 amine compounds Chemical class 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 title 1
- 150000003456 sulfonamides Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- JGABXKCIRPUBAD-UHFFFAOYSA-N 5-[1-(4-cyanophenyl)piperidin-4-yl]oxy-n-[1-(pyridin-4-ylmethyl)piperidin-4-yl]pyridine-2-carboxamide Chemical compound C=1C=C(OC2CCN(CC2)C=2C=CC(=CC=2)C#N)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=NC=C1 JGABXKCIRPUBAD-UHFFFAOYSA-N 0.000 abstract 1
- YXJGALVWDBKQFQ-UHFFFAOYSA-N 5-[1-[(4-chlorophenyl)methyl]piperidin-4-yl]oxy-n-[1-(pyridin-4-ylmethyl)piperidin-4-yl]-1-benzofuran-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1CN1CCC(OC=2C=C3C=C(OC3=CC=2)C(=O)NC2CCN(CC=3C=CN=CC=3)CC2)CC1 YXJGALVWDBKQFQ-UHFFFAOYSA-N 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- NKFLEFWUYAUDJV-UHFFFAOYSA-N pyridine-3-sulfonamide Chemical compound NS(=O)(=O)C1=CC=CN=C1 NKFLEFWUYAUDJV-UHFFFAOYSA-N 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98872107P | 2007-11-16 | 2007-11-16 | |
| US99055407P | 2007-11-27 | 2007-11-27 | |
| US99055807P | 2007-11-27 | 2007-11-27 | |
| US99118907P | 2007-11-29 | 2007-11-29 | |
| US1392407P | 2007-12-14 | 2007-12-14 | |
| PCT/US2008/083801 WO2009065131A1 (en) | 2007-11-16 | 2008-11-17 | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ585298A true NZ585298A (en) | 2012-08-31 |
Family
ID=40352415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ585298A NZ585298A (en) | 2007-11-16 | 2008-11-17 | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8119809B2 (enExample) |
| EP (1) | EP2231600B1 (enExample) |
| JP (1) | JP5544296B2 (enExample) |
| KR (1) | KR101573091B1 (enExample) |
| CN (1) | CN101910131B (enExample) |
| AU (3) | AU2008322426C1 (enExample) |
| BR (1) | BRPI0820171B8 (enExample) |
| CA (1) | CA2705947C (enExample) |
| EA (1) | EA019509B1 (enExample) |
| ES (1) | ES2552733T3 (enExample) |
| IL (1) | IL205624A (enExample) |
| MX (2) | MX2010005298A (enExample) |
| NZ (1) | NZ585298A (enExample) |
| WO (1) | WO2009065131A1 (enExample) |
| ZA (1) | ZA201003412B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008083124A1 (en) | 2006-12-28 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
| JP5544296B2 (ja) | 2007-11-16 | 2014-07-09 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物 |
| ES2553340T3 (es) * | 2007-12-12 | 2015-12-07 | Rigel Pharmaceuticals, Inc. | Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos |
| JP5658138B2 (ja) * | 2008-04-23 | 2015-01-21 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 代謝障害の処置のためのカルボキサミド化合物 |
| HUE025013T2 (hu) | 2009-01-12 | 2016-04-28 | Pfizer Ltd | Szulfonamid-származékok |
| CN102365275B (zh) | 2009-01-28 | 2014-09-24 | 里格尔药品股份有限公司 | 羧酰胺化合物及其使用方法 |
| SG176628A1 (en) | 2009-06-05 | 2012-01-30 | Link Medicine Corp | Aminopyrrolidinone derivatives and uses thereof |
| CN102666485A (zh) * | 2009-09-21 | 2012-09-12 | 霍夫曼-拉罗奇有限公司 | 烯烃羟吲哚衍生物及其用于治疗肥胖症，糖尿病和高脂血症的应用 |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| JPWO2011115106A1 (ja) * | 2010-03-16 | 2013-06-27 | 国立大学法人 東京大学 | 擬似運動療法のための医薬 |
| WO2011123681A1 (en) * | 2010-03-31 | 2011-10-06 | Rigel Pharmaceuticals, Inc. | Methods for using carboxamide, sulfonamide and amine compounds |
| JPWO2011142359A1 (ja) * | 2010-05-10 | 2013-07-22 | 日産化学工業株式会社 | スピロ化合物及びアディポネクチン受容体活性化薬 |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| US9079880B2 (en) | 2010-07-07 | 2015-07-14 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| US8697911B2 (en) | 2010-07-07 | 2014-04-15 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| JP5872552B2 (ja) | 2010-07-09 | 2016-03-01 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 化学化合物 |
| KR101764952B1 (ko) | 2010-07-29 | 2017-08-03 | 리겔 파마슈티칼스, 인크. | Ａｍｐｋ-활성화 헤테로시클릭 화합물 및 그의 사용 방법 |
| US9000154B2 (en) | 2010-10-19 | 2015-04-07 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| US9005909B2 (en) | 2011-01-06 | 2015-04-14 | Rigel Pharmaceuticals, Inc. | Whole blood assay for measuring AMPK activation |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9409884B2 (en) * | 2012-02-01 | 2016-08-09 | Rigel Pharmaceuticals, Inc. | 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| JP6233855B2 (ja) * | 2012-08-08 | 2017-11-22 | ノバルティス・ティーアゲズントハイト・アクチェンゲゼルシャフトＮｏｖａｒｔｉｓ Ｔｉｅｒｇｅｓｕｎｄｈｅｉｔ Ａｇ | 殺虫剤としての置換されたアジン類 |
| US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| EP2970177A1 (en) | 2013-03-15 | 2016-01-20 | Pfizer Inc. | Indole compounds that activate ampk |
| KR102318727B1 (ko) | 2013-07-31 | 2021-10-28 | 노파르티스 아게 | 1,4-이치환된 피리다진 유사체 및 smn-결핍-관련 상태를 치료하기 위한 그의 용도 |
| US20160214967A1 (en) * | 2013-09-30 | 2016-07-28 | The University Of Tokyo | Activator of adiponectin receptor |
| WO2016091042A1 (zh) * | 2014-12-08 | 2016-06-16 | 江苏恒瑞医药股份有限公司 | 吡啶甲酰胺类衍生物、其制备方法及其在医药上的应用 |
| CN114206851B (zh) * | 2019-04-26 | 2025-02-11 | 默沙东有限责任公司 | 可用于制备(2s,5r)-7-氧代-n-哌啶-4-基-6-(硫酸基)-1,6-二氮杂双环[3.2.1]辛烷-2-甲酰胺的中间体的制备方法 |
| WO2022072397A1 (en) | 2020-09-30 | 2022-04-07 | Bioverativ Therapeutics Inc. | Ampk activators and methods of use thereof |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8820115D0 (en) | 1988-08-24 | 1988-09-28 | Ici Plc | Insecticidal compounds |
| US6137002A (en) | 1993-07-22 | 2000-10-24 | Eli Lilly And Company | Glycoprotein IIb/IIIa antagonists |
| EA001437B1 (ru) | 1996-03-28 | 2001-02-26 | Глаксо Груп Лимитед | Производные пирролопирролона в качестве ингибиторов нейтрофильной эластазы |
| GB9715584D0 (en) | 1997-07-23 | 1997-10-01 | Eisai Co Ltd | Compounds |
| DE19738615A1 (de) | 1997-09-04 | 1999-03-11 | Clariant Gmbh | Neue Lichtschutzmittel auf Basis von sterisch gehinderten Aminen |
| US6589954B1 (en) | 1998-05-22 | 2003-07-08 | Scios, Inc. | Compounds and methods to treat cardiac failure and other disorders |
| AU772477B2 (en) | 1998-08-28 | 2004-04-29 | Scios Inc. | Inhibitors of p38-alpha kinase |
| US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| DK1218380T3 (da) | 1999-10-08 | 2004-03-15 | Gruenenthal Gmbh | Bicykliske imidazo-3-yl-aminoderivater substitueret i seksledsringen |
| US6436965B1 (en) | 2000-03-02 | 2002-08-20 | Merck Frosst Canada & Co. | PDE IV inhibiting amides, compositions and methods of treatment |
| US7273868B2 (en) | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| DE10050663A1 (de) | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
| EP1415987B1 (en) | 2000-10-20 | 2007-02-28 | Eisai R&D Management Co., Ltd. | Nitrogenous aromatic ring compounds as anti cancer agents |
| JP2005500996A (ja) | 2001-05-10 | 2005-01-13 | アボット ゲーエムベーハー ウント カンパニー カーゲー | アリールスルホンアミドエーテルおよびそれの使用方法 |
| BR0212123A (pt) | 2001-08-24 | 2004-07-20 | Upjohn Co | 7-aza[2.2.1]biciclo-heptanos substituìdos com arila para o tratamento de doenças |
| EP1425286B1 (en) | 2001-09-12 | 2007-02-28 | Pharmacia & Upjohn Company LLC | Substituted 7-aza-[2.2.1]bicycloheptanes for the treatment of diseases |
| US6858613B2 (en) | 2002-02-19 | 2005-02-22 | Pfizer Inc. | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease |
| WO2003072578A1 (en) | 2002-02-20 | 2003-09-04 | Pharmacia & Upjohn Company | Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity |
| AU2003245669A1 (en) | 2002-06-21 | 2004-01-06 | Cellular Genomics, Inc. | Certain aromatic monocycles as kinase modulators |
| CA2493457A1 (en) * | 2002-07-24 | 2004-01-29 | Tularik Inc. | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| RU2005118407A (ru) | 2002-12-13 | 2006-03-10 | СмитКлайн Бичем Корпорейшн (US) | Производные пиперидина в качестве антагонистов ccr5 |
| US7208491B2 (en) | 2003-02-07 | 2007-04-24 | Hoffmann-La Roche Inc. | N-monoacylated o-phenylenediamines |
| GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
| GB0314054D0 (en) | 2003-06-17 | 2003-07-23 | Pfizer Ltd | Amide derivatives as selective serotonin re-uptake inhibitors |
| TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| WO2005020921A2 (en) | 2003-08-29 | 2005-03-10 | Exelixis, Inc. | C-kit modulators and methods of use |
| US7196100B2 (en) | 2003-12-12 | 2007-03-27 | Eli Lilly And Company | Opioid receptor antagonists |
| US7544803B2 (en) | 2004-01-23 | 2009-06-09 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| RU2417225C2 (ru) * | 2004-03-25 | 2011-04-27 | Мемори Фармасьютиклз Корпорейшн | Индазолы, бензотиазолы, бензоизотиазолы, бензизоксазолы и их получение и применение |
| PE20060315A1 (es) | 2004-05-24 | 2006-05-15 | Irm Llc | Compuestos de tiazol como moduladores de ppar |
| CA2566526C (en) * | 2004-06-02 | 2012-10-23 | F. Hoffmann-La Roche Ag | Naphthaline derivatives useful as histamine-3-receptor ligands |
| ES2306170T3 (es) * | 2004-06-21 | 2008-11-01 | F. Hoffmann-La Roche Ag | Derivados de indol como antagonistas redeptores de histamina. |
| WO2006038594A1 (ja) * | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | Ｎ型カルシウムチャネル阻害薬 |
| MX2007004465A (es) | 2004-10-19 | 2007-05-07 | Hoffmann La Roche | Derivados de quinolina. |
| CA2584413A1 (en) | 2004-10-29 | 2006-05-04 | Astrazeneca Ab | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases |
| AU2005301568B2 (en) | 2004-11-08 | 2011-06-09 | Msd K.K. | Novel fused imidazole derivative |
| CA2588517A1 (en) | 2004-12-01 | 2006-06-08 | Devgen N.V. | 5-carboxamido substituted thiazole derivatives that interact with ion channels, in particular with ion channels from the kv family |
| US20080207634A1 (en) | 2004-12-17 | 2008-08-28 | Kristjan Gudmundsson | Chemical Compounds |
| AP2334A (en) | 2004-12-17 | 2011-12-06 | Glenmark Pharmaceuticals Sa | Novel heterocyclic compounds useful for the treatment of inflamatory and allergic disorders. |
| GB0428235D0 (en) | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Novel compounds |
| US20060187891A1 (en) | 2005-02-24 | 2006-08-24 | Jussi-Pekka Sairanen | Provision of services in a communication system |
| US7998974B2 (en) | 2005-03-03 | 2011-08-16 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
| MX2007011234A (es) | 2005-03-14 | 2007-11-12 | Transtech Pharma Inc | Derivados de benzazol, composiciones y metodos de uso en la forma de inhibidores de b-secretasa. |
| WO2006101434A1 (en) | 2005-03-22 | 2006-09-28 | Astrazeneca Ab | NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS |
| GB0508472D0 (en) | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
| EP1907376A2 (en) | 2005-07-05 | 2008-04-09 | Aryx Therapeutics, Inc. | Stereoisomeric pyridyl and pyridonyl compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
| KR20080048550A (ko) * | 2005-09-23 | 2008-06-02 | 메모리 파마슈티칼스 코포레이션 | 인다졸, 벤조티아졸, 벤조이소티아졸, 벤즈이속사졸,피라졸로피리딘, 이소티아졸로피리딘, 및 이들의 제법 및용도 |
| WO2007063000A1 (en) | 2005-11-30 | 2007-06-07 | F. Hoffmann-La Roche Ag | 5-substituted indole-2-carboxamide derivatives |
| WO2007062999A2 (en) | 2005-11-30 | 2007-06-07 | F. Hoffmann-La Roche Ag | 1,5-substituted indol-2-yl amide derivatives |
| EP1968967B1 (en) | 2005-11-30 | 2011-04-27 | F. Hoffmann-La Roche AG | 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives for use as h3 modulators |
| JP2009521451A (ja) * | 2005-12-21 | 2009-06-04 | シェーリング コーポレイション | ヒスタミンｈ３アンタゴニストとして有用な置換アニリン誘導体 |
| WO2007087548A2 (en) | 2006-01-25 | 2007-08-02 | Smithkline Beecham Corporation | Chemical compounds |
| AR059197A1 (es) | 2006-01-25 | 2008-03-19 | Smithkline Beecham Corp | Derivados de indazolo piridina para el tratamiento de hiv |
| US20090036429A1 (en) * | 2006-02-17 | 2009-02-05 | Ohler Norman E | Hydroxypiperidine Derivatives and Uses Thereof |
| WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
| EP2463283B1 (en) | 2006-04-20 | 2014-06-11 | Pfizer Products Inc. | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases |
| CA2651072A1 (en) * | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| CA2654792A1 (en) | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| JP2009539885A (ja) | 2006-06-13 | 2009-11-19 | メルク フロスト カナダ リミテツド | ステアロイルコエンザイムａデルタ−９デサチュラーゼの阻害剤としてのアザシクロペンタン誘導体 |
| TW200821303A (en) | 2006-08-08 | 2008-05-16 | Speedel Experimenta Ag | Organic compounds |
| WO2008083124A1 (en) * | 2006-12-28 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
| WO2008133975A1 (en) * | 2007-04-26 | 2008-11-06 | Avalon Pharmaceuticals | Multi-ring compounds and uses thereof |
| US8299057B2 (en) * | 2007-07-20 | 2012-10-30 | Nerviano Medical Sciences S.R.L. | Substituted indazole derivatives active as kinase inhibitors |
| JP5544296B2 (ja) | 2007-11-16 | 2014-07-09 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物 |
| ES2553340T3 (es) * | 2007-12-12 | 2015-12-07 | Rigel Pharmaceuticals, Inc. | Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos |
| JP2011516557A (ja) * | 2008-04-07 | 2011-05-26 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｇｐｒ１１９活性のモジュレーターとしての化合物および組成物 |
| JP5658138B2 (ja) | 2008-04-23 | 2015-01-21 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 代謝障害の処置のためのカルボキサミド化合物 |
| JP2010090067A (ja) * | 2008-10-09 | 2010-04-22 | Taisho Pharmaceutical Co Ltd | 含窒素複素環誘導体 |
-
2008
- 2008-11-17 JP JP2010534263A patent/JP5544296B2/ja not_active Expired - Fee Related
- 2008-11-17 EA EA201070619A patent/EA019509B1/ru not_active IP Right Cessation
- 2008-11-17 CA CA2705947A patent/CA2705947C/en active Active
- 2008-11-17 MX MX2010005298A patent/MX2010005298A/es active IP Right Grant
- 2008-11-17 ES ES08848677.4T patent/ES2552733T3/es active Active
- 2008-11-17 US US12/272,581 patent/US8119809B2/en active Active
- 2008-11-17 KR KR1020107013166A patent/KR101573091B1/ko not_active Expired - Fee Related
- 2008-11-17 MX MX2014005186A patent/MX382569B/es unknown
- 2008-11-17 AU AU2008322426A patent/AU2008322426C1/en not_active Ceased
- 2008-11-17 WO PCT/US2008/083801 patent/WO2009065131A1/en not_active Ceased
- 2008-11-17 BR BRPI0820171A patent/BRPI0820171B8/pt not_active IP Right Cessation
- 2008-11-17 NZ NZ585298A patent/NZ585298A/xx not_active IP Right Cessation
- 2008-11-17 CN CN200880124960.1A patent/CN101910131B/zh not_active Expired - Fee Related
- 2008-11-17 EP EP08848677.4A patent/EP2231600B1/en not_active Not-in-force
-
2010
- 2010-05-09 IL IL205624A patent/IL205624A/en active IP Right Grant
- 2010-05-14 ZA ZA2010/03412A patent/ZA201003412B/en unknown
-
2012
- 2012-01-11 US US13/348,380 patent/US8569340B2/en not_active Expired - Fee Related
-
2013
- 2013-10-14 US US14/053,325 patent/US9174964B2/en active Active
-
2014
- 2014-05-13 AU AU2014202572A patent/AU2014202572B2/en not_active Ceased
-
2017
- 2017-04-27 AU AU2017202766A patent/AU2017202766B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ588652A (en) | Carboxamide compounds for the treatment of metabolic disorders | |
| NZ596882A (en) | Disubstituted phthalazine hedgehog pathway antagonists | |
| NO20081434L (no) | 5-(fenylisoksazolyletoksy)-triazol-3-yl substituert pyridinsammensetninger for behandling av neurologisk, psykiatrisk eller smerteforstyrrelser | |
| PE20091656A1 (es) | Compuestos heterociclicos como inhibidores de la cinasa raf | |
| MA30983B1 (fr) | Composes chimiques et leurs utilisations | |
| LTPA2020525I1 (lt) | Kietos 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties formos | |
| NO20071549L (no) | Nye benzofuserte heteroalrylsulfamidderivater, anvendelige som anti-krampemidler | |
| NO20091599L (no) | Kjemiske forbindelser | |
| CL2012001221A1 (es) | Compuestos derivados de 4 -(1h-pirrol-1-il) pirimidin -2-ilamino y 4 -(1h-pirazol-1-il)- pirimidin-2-ilamino, inhibidores de quinasa; un compuesto isomerico; composicion farmaceutica; utiles en el tratamiento del asma, enfermedad pulmonar obstructiva cronica, colitis ulcerante, enfermedad de crohn, bronquitis, dermatitis, entre otras. | |
| NZ596467A (en) | L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators | |
| EA201070699A1 (ru) | Композиции 3-(6-(1-2,2-дифторбензо[d][1,3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты | |
| DE602007009865D1 (de) | 5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin-7-olderivate als cxcr2-antagonisten | |
| NO20053242L (no) | 4-substituerte benzimidazoler og deres anvendelse som inhibitorer av gastrisk sekresjon | |
| PE20130774A1 (es) | Compuestos heterociclicos activadores de ampk y metodos para emplearlos | |
| WO2009046841A8 (de) | Piperidin- und piperazinderivate zur behandlung von tumoren | |
| ATE473210T1 (de) | Substituierte pyrrolidinone als hemmer von 11- beta-hydroxysteroiddehydrogenase 1 | |
| EA200870474A1 (ru) | Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1 | |
| NO20081893L (no) | 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft | |
| PE20061366A1 (es) | Compuestos y composiciones como inhibidores de quinasa de proteina | |
| NO20090064L (no) | Pyrasoler som glucokinase aktivatorer | |
| NZ592714A (en) | Thieno[3,2-c]pyridine derivatives as kinase inhibitors for use in the treatment of cancer | |
| NO20092284L (no) | Progesteronreseptorantagonister | |
| WO2008130953A3 (en) | 2-imin0is0thiaz0le derivatives as cannabinoid receptor ligands | |
| NO20076424L (no) | N-koblete heterocykliske antagonister av P2Y1 reseptoren nyttige for behandling av tromboseforstyrrelser | |
| GEP20125711B (en) | Piperazine salt and method for their preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 NOV 2015 BY COMPUTER PACKAGES INC. Effective date: 20130126 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 NOV 2016 BY COMPUTER PACKAGES INC Effective date: 20151031 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 NOV 2017 BY COMPUTER PACKAGES INC Effective date: 20161101 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 NOV 2018 BY COMPUTER PACKAGES INC Effective date: 20171031 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 NOV 2019 BY COMPUTER PACKAGES INC Effective date: 20181031 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 NOV 2020 BY COMPUTER PACKAGES INC Effective date: 20191031 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 NOV 2021 BY COMPUTER PACKAGES INC Effective date: 20201031 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 NOV 2022 BY COMPUTER PACKAGES INC Effective date: 20211030 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 NOV 2023 BY COMPUTER PACKAGES INC Effective date: 20221030 |
|
| LAPS | Patent lapsed |